<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate <z:hpo ids='HP_0000726'>dementia</z:hpo> (<z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>) associated with neuropsychiatric symptoms </plain></SENT>
<SENT sid="1" pm="."><plain>Patients scored 9 to 23 on the SKT cognitive battery, at least 6 on the Neuropsychiatric Inventory (NPI), with at least one of four key items rated at least 4 </plain></SENT>
<SENT sid="2" pm="."><plain>Primary outcomes were the changes from baseline to week 24 in the SKT and NPI total scores </plain></SENT>
<SENT sid="3" pm="."><plain>The ADCS Clinical Global Impression of Change (ADCS-CGIC), Verbal Fluency Test, Activities of Daily Living International Scale (ADL-IS), DEMQOL-Proxy quality-of-life scale and 11-point box scales for <z:hpo ids='HP_0000360'>tinnitus</z:hpo> and dizziness were secondary outcome measures </plain></SENT>
<SENT sid="4" pm="."><plain>Patients treated with EGb 761(®) (n = 200) improved by 2.2 ± 3.5 points (mean ± sd) on the SKT total score, whereas those receiving placebo (n = 202) changed only slightly by 0.3 ± 3.7 points </plain></SENT>
<SENT sid="5" pm="."><plain>The NPI composite score improved by 4.6 ± 7.1 in the EGb 761(®)-treated group and by 2.1 ± 6.5 in the placebo group </plain></SENT>
<SENT sid="6" pm="."><plain>Both drug-placebo comparisons were significant at p &lt; 0.001 </plain></SENT>
<SENT sid="7" pm="."><plain>Patients treated with EGb 761(®) also showed a more favourable course in most of the secondary efficacy variables </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, treatment with EGb 761(®) at a once-daily dose of 240 mg was safe and resulted in a significant and clinically relevant improvement in cognition, psychopathology, functional measures and quality of life of patients and caregivers </plain></SENT>
</text></document>